|
HF Frailty Simplified, Aetna Covers AI-Plaque, and A New IVL
January 8, 2026
|
|
|
|
|
Together with
|
|
|
|
|
A new registry analysis out of Japan suggests we may be able to simplify how we classify heart failure frailty without losing accuracy, allowing us to screen for HF mortality risk in faster and more practical ways.
- In the context of HF, frailty is defined as increased vulnerability due to physical and cognitive decline, muscle loss, and inflammation.
- One option for determining frailty is the Clinical Frailty Scale (CFS), a 9-point (1 = very fit, 9 = terminally ill) tool that summarizes the level of fitness or frailty in adults over 65.
- Physicians use the CFS as a simple visual tool, but whether it adequately captures physical and cognitive decline was unproven till now.
To see how CFS stacks up against comprehensive physical testing, researchers categorized 3.9k patients hospitalized with HF into six CFS categories (1-2, 3, 4, 5, 6, 7-9) and compared their results against function metrics (gait speed, SPPB, grip strength, etc) and cognitive assessment (Mini-Cog test) and found that CFS could more than stand on its own.
- Physical function metrics and Mini-Cog scores progressively worsened with increasing CFS severity, demonstrating the scale captures both physical and cognitive vulnerability.
- Over 2-year follow-up, 18.6% of patients died, with mortality increasing across higher CFS scores.
- Adding CFS to prognostic models significantly improved predictions compared to models based on SPPB and Mini-Cog test alone.
- The CFS was also able to independently predict a patient’s mortality beyond conventional functional testing, meaning it could capture something other tests don’t.
Even with comprehensive performance-based frailty assessments available, the simple visual CFS demonstrated much more accurate prognostic value, challenging assumptions that formal testing provides better risk stratification.
The real kicker comes in how much easier the tool makes physicians’ lives, since CFS offers a more practical option that goes hand in hand with performance-based frailty assessments while not requiring specialized equipment.
The Takeaway
Sometimes it seems like more is better, but in the case of HF’s impact on a patient’s body, keeping it simple might be the best way to quantify risk. If nothing else, this study could encourage physicians to assess their patients in a more pragmatic way.
|
|
How Vista AI Helps Solve the Technologist Shortage
Fewer than 2% of MRI scanners are routinely used for cardiac imaging—mainly due to a shortage of trained technologists amid rising demand. Vista AI addresses this challenge by automating CMR scanning, empowering technologists of all experience levels to deliver high-quality cardiac exams consistently and efficiently.
|
|
5,600 Ways to Improve Your Cardiac Ultrasound Workflow
AI-powered measurements can enhance the way you acquire and interpret cardiac ultrasound. Learn how AI-powered ultrasound can help you overcome everyday limitations in echo. Read Siemens Healthineers’ white paper on how its AI software provides 5,600+ automated measurements to help improve workflow efficiency, consistency, and clinical confidence.
|
|
Identify and Treat Cardiovascular Disease
Complex care pathways make getting patients to the next step a challenge. See how Tempus Next, an AI enabled care pathway platform, helps providers identify and reduce under treatment in cardiovascular disease by adding an intelligent layer onto their routinely generated EHR data.
|
|
- Vektor vMap’s Proof of Concept: A study of four patients with unstable ventricular tachycardias found that Vektor’s vMap correctly identified 100% of successful ablation sites through substrate mapping. The multi-strategic approach combined AI ECG localization of VT exit sites, pace-mapping, and slow conduction channel mapping within scar tissue successfully eliminated all nine induced VTs in the four patients. At six-month follow-up, no patients experienced recurrent VTs that required device therapy or mortality, suggesting that vMap can improve ablation outcomes for unstable VT cases.
- W.L. Gore Acquires Conformal: Jumpstarting its expansion into endovascular tech, W.L. Gore acquired Conformal Medical, which develops the CLAAS AcuFORM System for LAAO. The investigational device uses a nitinol frame and foam matrix to conform to different LAA anatomies with just two sizes. This could potentially enable same-day procedures without general anesthesia or hospitalization, however the system is currently in clinical testing and not commercially available.
- CPT Codes for AI Hemo-Assessment: The AMA published a new Category III CPT code (1036T) for noninvasive augmentative AI hemodynamic assessment, which will cover technologies like Sensydia’s Cardiac Performance System. The CPS technology uses non-invasive sensors and AI to assess a patient’s blood flow in real-time for HF and pulmonary hypertension. The platform is currently undergoing a multi-center pivotal study comparing its accuracy to invasive right heart catheterization to support FDA submission. The code becomes effective July 1, 2026.
- It’s a Kind of MAGiC: The FDA approved Stereotaxis’ robotically controlled MAGiC radiofrequency ablation catheter for treating supraventricular tachycardia. The catheter uses computer-controlled magnetic fields instead of manual steering to offer physicians precise navigation in hearts with anatomical complications like congenital heart disease. Stereotaxis also sees the approval as validation of its Robotic Magnetic Navigation technology as a mainstream electrophysiology approach while strengthening the value proposition for EP labs currently using its systems.
- CardioOne Launches CardioOne Connect: CardioOne launched the CardioOne Connect platform that combines ambulatory cardiac diagnostics, chronic care management, and remote patient monitoring. The platform integrates CardioDiagnostics (acquired April 2025) into a unified system that connects with existing EMRs while providing care planning through CardioOne’s cloud-based Rhythm technology. Early results from pilot practices show improved patient engagement, earlier interventions, and reduced provider workload. CardiOne started with the goal of helping cardiologists go private, so this launch represents a diversification of its offerings into RPM and care management.
- Corsera’s Series A: Corsera Health raised $80M in Series A financing to support the development of its PCSK9i, COR-1004. Alongside the funding announcement, Corsera also stated it would begin Phase 1 dosing for COR-1004 with initial proof-of-concept data expected in 2026. Corsera hopes to differentiate its PCK9i through its once-annual dosing and by combining it with AI-enabled lifetime cardiovascular risk prediction through its Klotho platform.
- Private Payors Start Covering AI Plaque Analysis: Now that AI-based plaque analysis has a Category 1 CPT code, private insurance companies are starting to loosen their reimbursement purse strings. Aetna became the latest private payor to implement coverage, joining Humana, Cigna, and UnitedHealthcare. The moves are benefiting developers of AI plaque analysis algorithms, including Heartflow, Cleerly, Elucid, and others.
- Cardio Diagnostics Enters India: Cardio Diagnostics announced a partnership with Aimil and Dr. Lal PathLabs to launch its PrecisionCHD test in India, marking the company’s first international expansion. Integration within Dr. Lal PathLabs’ 290+ laboratory network is underway, with commercial rollout expected in 2026. Cardio Diagnostics believes the partnership will help address India’s significant cardiovascular disease burden.
- Arrowhead’s Obesity Drugs: Arrowhead Pharmaceuticals published interim Phase 1/2a results for its RNA-based obesity treatments – ARO-INHBE and ARO-ALK7. ARO-INHBE combined with tirzepatide achieved 9.4% weight loss at week 16 in obese diabetic patients, doubling tirzepatide alone (4.8%), with three-fold improvements in visceral fat (-23.2%), total fat (-15.4%), and liver fat (-76.7%) reductions. Meanwhile, ARO-ALK7 showed fat cell gene inactivation in humans, achieving 88% mean ALK7 mRNA reduction and 14.1% placebo-adjusted visceral fat reduction at week 8.
- Another IVL in the EU: Adding to Europe’s IVL duopoly, Spectrumedics received CE Mark certification for its Sonico-CX Intravascular Lithotripsy System. Sonico-CX treats calcified coronary lesions using acoustic pressure waves to target superficial and deep plaques. The device features 360° energy delivery, up to 120 pulses per catheter, a low crossing profile, and seven balloon sizes (2.5-4.0 mm). The approval makes Spectrumedics’ platform the third in Europe, coming nearly ten years after Shockwave’s first IVL approval in the EU.
- HUYABIO’s Anti-AFib Drug: HUYABIO announced positive Phase 1 results for its antiarrhythmic drug, HBI-3000 (sulcardine sulfate), that can help with atrial fibrillation. HBI-3000 seemed to be well-tolerated in healthy volunteers and showed it could meaningfully inhibit sodium ion channels in heart tissue. The drug’s unique inhibition method targets multiple atrial and ventricular ion channels while limiting QT prolongation risks associated with current antiarrhythmic drugs, potentially addressing the unmet need for safer AFib treatments.
|
|
Cracking the Code of ECG Analysis with Monebo’s AI Genetic Algorithm
How do you teach a computer to recognize the complex patterns in an ECG signal? Discover how Monebo found the answer by blending human expertise and a little evolutionary magic in this article that breaks down the advantages of genetic algorithms in ECG analysis.
|
|
What Every Cardiologist Needs to Watch for in Heart Failure
Patients with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) face a high risk of hospitalization for heart failure and cardiovascular death, even with guideline-directed medical treatment. Hear from Bayer’s Dr. Alanna Morris-Simon as she shares common heart failure signs to look out for.
|
|
PIA’s Post-Processing Solution
Advanced cardiac imaging often calls for a time-consuming post-processing step, requiring costly software, hardware, and training. See how PIA provides this post-processing at lower cost, improved consistency, and greater efficiency.
|
|
- From CPACS to CVIS: Cardiovascular imaging has come a long way from CPACS. Explore the evolution of cardiology image and data management in this Merge executive brief, and see what makes CVIS such a significant advancement.
- The Largest Registry on Plaque Analysis in CAD: What if 50% of your CCTA patients could benefit from an adjustment to their treatment plan? Read more about Heartflow’s DECIDE registry that demonstrates how Heartflow Plaque Analysis using its Plaque Staging software empowers physicians with clinical insights that lead to real-world impact.
- GLS Analysis of Us2.ai’s Fully-Automated Software: Ten years after the first head-to-head comparison of 2D echocardiography, the latest review suggests Us2.ai is among the easiest to use and integrate. Read the study to learn about how Us2.ai’s software requires zero operator input, operates without human intervention, and leads to high agreement with traditional semi-automated speckle- tracking software solutions.
- Assessing CAD with Circle CVI: Did you know that Circle CVI offers a suite of cardiac CT tools for the assessment of coronary artery disease? See how Circle combines heart function segmentation, automated plaque analysis, CAC scoring, reporting, and viewing in a single dedicated Cardiac CT package.
- Explore Vitrea Advanced Visualization: Discover Canon Medical Healthcare IT’s suite of advanced imaging workflows designed to increase efficiency in cardiovascular imaging, and facilitate the assessment, diagnosis, and treatment of cardiovascular diseases. These cutting-edge tools support the delivery of faster, more accurate care while integrating seamlessly into clinical workflow.
|
|
|
|
|
